Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: florbetapir (18F) Clear all
Completed Phase 2 Interventional Results available

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

NCT00857532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2013 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Results available

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2013 · Synced Sep 27, 2026, 6:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Continuation of The Kronos Early Estrogen Prevention Study (KEEPS)

NCT03718494
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
49 Years to 72 Years · Female only
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 27, 2026, 6:46 PM EDT
Completed No phase listed Observational

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

NCT04726527
View directory record Official record
Conditions
Primary Progressive Aphasia, Alzheimer Disease, Dementia
Interventions
Florbetapir F 18, Positron Emission Tomography
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

NCT05164536
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Amyvid
Drug
Lead sponsor
Invicro
Other
Eligibility
70 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

NCT00855868
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, [11C]-PIB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 3 Interventional Results available

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

NCT01447719
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Cypress, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03545789
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
[18F]MNI-958
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 27, 2026, 6:46 PM EDT
Recruiting No phase listed Observational

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

NCT03019757
View directory record Official record
Conditions
Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Interventions
DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, Clinical Assessment
Radiation · Genetic · Procedure + 1 more
Lead sponsor
Douglas Scharre
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

NCT00857415
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

NCT01565330
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 17, 2012 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Not applicable Interventional Results available

Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound

NCT04118764
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Definity, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid
Device · Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Sep 27, 2026, 6:46 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

NCT02051764
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Florbetapir F 18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 27, 2026, 6:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Risk Prediction for Alzheimer Dementia With Brain Imaging and Genetics

NCT03641768
View directory record Official record
Conditions
Alzheimer Dementia, Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
MRI, PET, 18F-Florbetapir, Radioligand 18F-AV-1451
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

NCT00702143
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
15
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

NCT02016560
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 27, 2026, 6:46 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 3 Interventional Results available

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

NCT01400425
View directory record Official record
Conditions
Progressive Cognitive Decline
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jenkintown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 27, 2026, 6:46 PM EDT
Terminated Phase 4 Interventional Results available

The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

NCT03040427
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 27, 2026, 6:46 PM EDT
Terminated Phase 4 Interventional Results available

Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy

NCT03333551
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F18 Florbetapir (amyvid) cardiac PET/CT imaging
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 27, 2026, 6:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

NCT02103894
View directory record Official record
Conditions
Alzheimer's Disease (AD), Parkinson's Disease (PD), Chronic Traumatic Encephalopathy (CTE), Progressive Supranuclear Palsy (PSP), Frontal Temporal Dementia (FTD), Pick's Disease, Tauopathies
Interventions
[18F]T807 ([18F]MNI-777)
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 27, 2026, 6:46 PM EDT